Velcade (bortezomib)
Janssen; generics available · Proteasome Inhibitor
What is Velcade? Velcade (bortezomib) is the first proteasome inhibitor approved for cancer therapy, used in multiple myeloma (newly diagnosed and relapsed/refractory) and relapsed/refractory mantle cell lymphoma. SC injection has replaced IV administration for most patients due to less neuropathy.
About Velcade
| Brand Name | Velcade |
| Generic / INN | bortezomib |
| Drug Class | Proteasome Inhibitor |
| Manufacturer | Janssen; generics available |
| Administration | Intravenous (IV) injection or Subcutaneous (SC) injection |
| FDA Approval | 2003 |
FDA-Approved Uses for Velcade
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Multiple myeloma — newly diagnosed and relapsed/refractory
- Mantle cell lymphoma — relapsed/refractory (at least 1 prior therapy)
How Does Velcade Work?
Bortezomib reversibly inhibits the 26S proteasome, the cellular complex responsible for degrading ubiquitin-tagged proteins. This blocks the breakdown of pro-apoptotic factors and disrupts multiple signaling pathways (NF-κB, unfolded protein response) that myeloma and MCL cells depend on for survival, triggering apoptosis.
Dosage & Administration
Standard: 1.3 mg/m² SC or IV. SC is preferred — same efficacy, less neuropathy. Various schedules (weekly, twice-weekly) depending on regimen and indication. Part of many backbone regimens (VRd, VCD, VMP, VTd, D-Vd).
Warnings, Precautions & Side Effects
General Warning
Peripheral neuropathy — cumulative, can be severe and irreversible (SC has significantly less); dose reduce or discontinue. Herpes zoster reactivation — antiviral prophylaxis recommended. Hypotension. Cardiac toxicity. Pulmonary toxicity. Hepatic toxicity. Thrombocytopenia. Embryo-fetal toxicity.
Common Side Effects
- Peripheral neuropathy
- Nausea
- Fatigue
- Thrombocytopenia
- Diarrhea
- Constipation
- Anorexia
- Fever
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Store at room temperature 25°C (77°F). Protect from light.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Velcade is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Velcade. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Velcade
Velcade was the first proteasome inhibitor approved for cancer — revolutionizing myeloma treatment. It blocks the proteasome, the cell's protein recycling machinery, causing toxic accumulation of proteins that triggers cancer cell death.
Subcutaneous is preferred — multiple studies show equivalent efficacy with significantly less peripheral neuropathy compared to IV. SC bortezomib is now standard for most patients.
Yes — bortezomib significantly increases the risk of herpes zoster (shingles) reactivation. Antiviral prophylaxis (acyclovir or valacyclovir) is recommended throughout treatment.
Yes. Generic bortezomib 3.5 mg/vial is available from multiple manufacturers.
Related Medications & Conditions
Related Medications
Kyprolis (carfilzomib) · Ninlaro (ixazomib) · Revlimid (lenalidomide) · Darzalex (daratumumab) · Abecma
Related Conditions
Multiple myeloma · Mantle cell lymphoma (MCL) · Relapsed/refractory myeloma